Eagle Pharmaceuticals, Inc.
EGRX · OTC
3/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | – | $0 | $0 | $0 |
| % Growth | – | 84.6% | -8.7% | – |
| Cost of Goods Sold | – | $0 | $0 | $0 |
| Gross Profit | – | $0 | $0 | $0 |
| % Margin | – | 70% | 75.4% | 75.8% |
| R&D Expenses | – | $0 | $0 | $0 |
| G&A Expenses | – | $0 | $0 | $0 |
| SG&A Expenses | – | $0 | $0 | $0 |
| Sales & Mktg Exp. | – | $0 | $0 | $0 |
| Other Operating Expenses | – | $0 | $0 | $0 |
| Operating Expenses | – | $0 | $0 | $0 |
| Operating Income | – | $0 | $0 | $0 |
| % Margin | – | 25.6% | 1.6% | 17.5% |
| Other Income/Exp. Net | – | -$0 | -$0 | -$0 |
| Pre-Tax Income | – | $0 | -$0 | $0 |
| Tax Expense | – | $0 | $0 | $0 |
| Net Income | – | $0 | -$0 | $0 |
| % Margin | – | 11.3% | -5% | 6.4% |
| EPS | – | 2.76 | -0.66 | 0.89 |
| % Growth | – | 518.2% | -174.2% | – |
| EPS Diluted | – | 2.73 | -0.66 | 0.87 |
| Weighted Avg Shares Out | – | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | – | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $0 | $0 | $0 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | – | $0 | $0 | $0 |
| EBITDA | – | $0 | $0 | $0 |
| % Margin | – | 24.5% | 0.5% | 16% |